Recent presentations / interviews

Webcast of CEO Malcolm Young's presentation at the Biotech Showcase Conference 2012 in San Francisco, 11 January 2011 at 1830 UK time (continues to be available after the event)

Click here for a link to the slides and audio from the presentation

Proactive Investors e-Therapeutics StockTube Interview:

"Daniel Elger, CFO at e-Therapeutics (LON:ETX), tells Proactive Investors that 2012 is the year when the meaningful data starts to come through after this year's successful recapitalisation. Daniel explains how the e-Therapeutics proprietary network pharmacology platform works and its advantages in drug discovery"

The full interview can be seen on proactiveinvestors.co.uk

Proactive Investors One2One Forum presentation (9th November 2011)

Forthcoming events and presentations

Molecular Medicine Triconference Meeting - February 2012

triconference.com

Professor Malcolm Young will give a keynote lecture entitled 'De-risking Drug Discovery using Network Pharmacology' in the conference track 'De-risking Drug Discovery.' He will also co-lead a short course on Network Pharmacology sponsored by e-Therapeutics on 20 Feb 2012 (further details are available here).

AIM rule 26 particulars

The following information is being disclosed for the purposes of Rule 26 of the AIM Rules for Companies.

About e-Therapeutics

The following links contains information about the Company:  About Us

The following links contain information about our Directors including details of committees and their members: Board of Directors, Directors’ Responsibilities and Corporate Governance.

Country of Incorporation and Main Country of Operation

Country of Incorporation: England and Wales.

Company Number: 4304473.

Main Country of Operation: The head office and main operations are in Newcastle-upon-Tyne, England.

Current Constitutional Documents

The following links contain details of the constitutional documents for e-Therapeutics:

• Articles of Association

Details of Any Other Exchanges or Trading Platforms

The Company is not listed on any other exchanges or trading platforms.

Number of Securities in Issue

The Company’s share capital consists of an issued share capital of 138,126,467 ordinary shares in issue, with a nominal value of 0.1 pence each (”Ordinary Shares”), each share having equal voting rights. The company does not hold any Ordinary Shares in treasury. So far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 75.5%. At 14 March 2011, the following interests of shareholders in excess of 3% (significant shareholders), have been notified to the company:

Significant Shareholders and shareholdings

• Invesco - 65,384,615 (47.3%)
  

• Malcolm Young - 20,620,482 (14.9%)

• Gartmore Investment Limited - 15,396,408 (11.1%)

• Octopus Group – 8,768,508 (6.3%)

• Newcastle University Holdings Limited - 6,744,000 (4.9%)

• Credit Suisse Client Nominees (UK) Limited is the nominee for RAB Special Situations (Master) Fund LLP- 4,557,950 (3.3%)

Details of any restrictions on the transfer of securities

There are no restrictions on the transfer of securities.

Financial Reports

The annual reports, accounts, and interim results can be accessed as pdf documents via the following link: Reports And Accounts

Notifications, Admission Document and Circulars

All Stock Exchange Regulatory Announcements issued in the last 12 months may be accessed as pdf documents via the following links:

• Showcase presentation & 2012 goals (10 January 2012)
• Director/PDMR Shareholding (30 November 2011)
  
• Notification of Transactions of Directors (27 October 2011)
• Power behind the throne patent granted (26 September 2011)
• Notice of interim results (21 September 2011)
• Results of AGM Resolutions Passed (12 September 2011)
• Director/PDMR shareholding (17 August 2011)
• Director/PDMR shareholding (15 August 2011)
• Director/PDMR shareholding (9 August 2011)
• Annual report available (28 July 2011)
• Notification of Transactions of Directors (28 July 2011)
• Preliminary results and Business Update (25 July 2011)
• Directorate Change (13 June 2011)
• Issue of Equity (6 June 2011)
• Director's Award of Options (24 May 2011)
• Notification of Transactions of Directors (23 May 2011)
• Notification of Transactions of Directors (15 March 2011)
• Notification of Major Interest in Shares (15 March 2011)
• Re-statement of Directors' Interests (10 March 2011)
• Notification of major interest in shares (10 March 2011)
• Completion of the Placings (7 March 2011)
• Notification of Transactions of Directors (4 March 2011)
• Notification of Transactions of Directors (2 March 2011)
• Placing of new shares (16 February 2011)
• Conditional placing with new and existing institutional investors (15 February 2011)
• Issue of Equity (03 February 2011)
• Board appoints Stephen Self to direct development (6 December 2010)
• Interim Results (29 October 2010)
• AGM statement (08 Sept 2010)
• Annual Report and Accounts (30 July 2010)
• Issue of Equity (28 July 2010)
• Directors' Interests (02 July 2010)
• Annual Results (29 June 2010)
• Change of Adviser (25 May 2010)

• Earlier announcements and circulars

Advisers

The following link has details of the Company’s Nominated Adviser and other key advisers: Advisers

Updated 10 January 2012